Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy
NCT06811233Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2025
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of succimer, edetate calcium disodium in acute myeloid leukemia (AML), Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Started May 2025; status: recruiting.
02
Drugs
succimeredetate calcium disodium
03
Conditions
acute myeloid leukemia (AML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06811233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811233.